$swkh 2023 Q2 10-Q

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$9.497M	$9.411M	$11.13M
YoY Change	36.8%	-15.45%	18.79%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.315M	$2.540M	$3.160M
YoY Change	-23.29%	-19.62%	9.34%
% of Gross Profit
Research & Development	$1.509M	$719.0K	$1.901M
YoY Change	1.96%	-62.18%	22.65%
% of Gross Profit
Depreciation & Amortization	$637.0K	$648.0K	$704.0K
YoY Change	1.76%	-7.95%	-58.1%
% of Gross Profit
Operating Expenses	$1.509M	$719.0K	$5.765M
YoY Change	1.96%	-87.53%	-5.65%
Operating Profit
YoY Change
Interest Expense	$363.0K	$182.0K	-$801.0K
YoY Change	353.75%	-122.72%	-174.86%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	$5.388M	$4.526M	$4.565M
YoY Change	621.29%	-0.85%	5.43%
Income Tax	$1.454M	-$109.0K	$1.087M
% Of Pretax Income	26.99%	-2.41%	23.81%
Net Earnings	$3.934M	$4.635M	$3.478M
YoY Change	596.28%	33.27%	2.63%
Net Earnings / Revenue	41.42%	49.25%	31.25%
Basic Earnings Per Share	$0.31	$0.36	$0.27
Diluted Earnings Per Share	$0.31	$0.36	$269.9K
COMMON SHARES
Basic Shares Outstanding	12.82M shares	12.82B shares	12.83M shares
Diluted Shares Outstanding	12.79M shares	12.88M shares	12.89M shares

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.805M	$3.244M	$42.41M
YoY Change	-87.76%	-92.35%	1015.92%
Cash & Equivalents	$6.805M	$3.244M	$41.40M
Short-Term Investments			$1.006M
Other Short-Term Assets	$1.885M	$1.287M	$1.576M
YoY Change	37.99%	-18.34%	57.6%
Inventory
Prepaid Expenses
Receivables	$4.381M	$4.345M	$1.979M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.07M	$8.876M	$45.96M
YoY Change	-77.79%	-80.69%	-78.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.598M	$5.627M	$5.991M
YoY Change	-7.79%	-6.08%	8.93%
Goodwill	$8.404M	$8.404M
YoY Change	0.0%
Intangibles	$7.339M	$7.764M
YoY Change	-18.83%
Long-Term Investments	$59.00K	$66.00K	$3.597M
YoY Change	-98.36%	-98.17%	-2.78%
Other Assets	$3.123M	$2.401M	$24.25M
YoY Change	68.08%	-90.1%	-21.76%
Total Long-Term Assets	$277.4M	$291.9M	$240.0M
YoY Change	22.96%	21.61%	297.33%
TOTAL ASSETS
Total Short-Term Assets	$13.07M	$8.876M	$45.96M
Total Long-Term Assets	$277.4M	$291.9M	$240.0M
Total Assets	$290.4M	$300.7M	$286.0M
YoY Change	2.12%	5.17%	3.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.966M	$1.800M	$4.863M
YoY Change	6.84%	-62.99%	21.58%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$10.48M	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.996M	$12.32M	$4.863M
YoY Change	7.93%	153.24%	-68.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.362M	$2.837M	$10.29M
YoY Change	48.65%	-72.42%	-42.53%
Total Long-Term Liabilities	$2.362M	$2.837M	$10.29M
YoY Change	48.65%	-72.42%	-42.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.996M	$12.32M	$4.863M
Total Long-Term Liabilities	$2.362M	$2.837M	$10.29M
Total Liabilities	$16.56M	$26.35M	$15.15M
YoY Change	28.41%	73.93%	-54.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.152B	-$4.156B
YoY Change	-0.2%
Common Stock	$12.00K	$12.00K
YoY Change	-7.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$273.9M	$274.4M	$270.8M
YoY Change
Total Liabilities & Shareholders Equity	$290.4M	$300.7M	$286.0M
YoY Change	2.12%	5.17%	3.16%

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	$3.934M	$4.635M	$3.478M
YoY Change	596.28%	33.27%	2.63%
Depreciation, Depletion And Amortization	$637.0K	$648.0K	$704.0K
YoY Change	1.76%	-7.95%	-58.1%
Cash From Operating Activities	$4.724M	$664.0K	$4.255M
YoY Change	-649.3%	-84.39%	-2.63%
INVESTING ACTIVITIES
Capital Expenditures	$183.0K	$8.000K	-$58.00K
YoY Change	-445.28%	-113.79%	-81.88%
Acquisitions
YoY Change
Other Investing Activities	$14.97M	-$11.07M	-$5.653M
YoY Change	2.33%	95.9%	16.56%
Cash From Investing Activities	$14.79M	-$11.08M	-$5.711M
YoY Change	1.45%	94.05%	10.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-15.95M	$7.506M	-8.000K
YoY Change		-93925.0%	-98.67%
NET CHANGE
Cash From Operating Activities	4.724M	$664.0K	4.255M
Cash From Investing Activities	14.79M	-$11.08M	-5.711M
Cash From Financing Activities	-15.95M	$7.506M	-8.000K
Net Change In Cash	3.561M	-$2.912M	-1.464M
YoY Change	-74.04%	98.91%	4.57%
FREE CASH FLOW
Cash From Operating Activities	$4.724M	$664.0K	$4.255M
Capital Expenditures	$183.0K	$8.000K	-$58.00K
Free Cash Flow	$4.541M	$656.0K	$4.313M
YoY Change	-662.7%	-84.79%	-8.04%

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001089907
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures		usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax		usd
CY2022Q1	swkh	Derivative Instrument Receivable DerivativeInstrumentReceivable		usd
CY2022Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs		usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery		usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery		usd
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest		usd
CY2023Q1	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39184
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	SWK Holdings Corporation
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0435679
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	14755 Preston Road
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 105
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dallas
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	75254
CY2023Q1	dei	City Area Code CityAreaCode	(972)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	687-7250
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	SWKH
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12815167	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3244000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6156000	usd
CY2023Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	4345000	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	3094000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1287000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1114000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	8876000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10364000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11786000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11846000	usd
CY2023Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	237038000	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	236555000	usd
CY2023Q1	us-gaap	Derivative Instruments And Hedges DerivativeInstrumentsAndHedges	2750000	usd
CY2022Q4	us-gaap	Derivative Instruments And Hedges DerivativeInstrumentsAndHedges	2750000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	66000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	76000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	27128000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	24480000	usd
CY2023Q1	swkh	Warrant Assets WarrantAssets	683000	usd
CY2022Q4	swkh	Warrant Assets WarrantAssets	1220000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7764000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8190000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	8404000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	8404000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5627000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5840000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2401000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1742000	usd
CY2023Q1	us-gaap	Assets Assets	300737000	usd
CY2022Q4	us-gaap	Assets Assets	299621000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1833000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3902000	usd
CY2023Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	10482000	usd
CY2022Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	2445000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	12315000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6347000	usd
CY2023Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11200000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11200000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2837000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2145000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	26352000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	19692000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12830399	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12830399	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12843157	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12843157	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4430426000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4430922000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4156053000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4151005000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	274385000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	279929000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	300737000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	299621000	usd
CY2023Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	9260000	usd
CY2022Q1	us-gaap	Interest And Fee Income Loans And Leases InterestAndFeeIncomeLoansAndLeases	10415000	usd
CY2023Q1	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	118000	usd
CY2022Q1	swkh	Pharmaceutical Development Revenue PharmaceuticalDevelopmentRevenue	236000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	33000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	480000	usd
CY2023Q1	us-gaap	Revenues Revenues	9411000	usd
CY2022Q1	us-gaap	Revenues Revenues	11131000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	182000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	80000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	719000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1901000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	648000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	704000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2540000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3160000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	-5322000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	-5286000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-982000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-693000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-28000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	186000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4526000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4565000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-109000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1087000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	3478000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12833000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12830000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12875000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12888000	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	279929000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	35000	usd
CY2023Q1	swkh	Effect Of Adoption Of Accounting Standard EffectOfAdoptionOfAccountingStandard	-9683000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	531000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	4635000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	274385000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	267236000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	85000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	3478000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	270799000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	3478000	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	68000	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	56000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	15000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	14000	usd
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-122000	usd
CY2022Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	1079000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	982000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	693000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-28000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	186000	usd
CY2023Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	1466000	usd
CY2022Q1	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	421000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	351000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	734000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	35000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	85000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	648000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	704000	usd
CY2023Q1	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	1251000	usd
CY2022Q1	us-gaap	Increase Decrease In Interest And Dividends Receivable IncreaseDecreaseInInterestAndDividendsReceivable	176000	usd
CY2023Q1	swkh	Derivative Instrument Receivable DerivativeInstrumentReceivable	-388000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	915000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	225000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1412000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-270000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	664000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4311000	usd
CY2023Q1	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	12990000	usd
CY2022Q1	us-gaap	Payments To Acquire Finance Receivables PaymentsToAcquireFinanceReceivables	22700000	usd
CY2023Q1	swkh	Proceeds Repayment Of Finance Receivables ProceedsRepaymentOfFinanceReceivables	1906000	usd
CY2022Q1	swkh	Proceeds Repayment Of Finance Receivables ProceedsRepaymentOfFinanceReceivables	16978000	usd
CY2023Q1	swkh	Marketable Investment Principal Payment MarketableInvestmentPrincipalPayment	10000	usd
CY2022Q1	swkh	Marketable Investment Principal Payment MarketableInvestmentPrincipalPayment	13000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11082000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5767000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	8037000	usd
CY2022Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-8000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	531000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7506000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2912000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1464000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6156000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	42863000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3244000	usd
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41399000	usd
CY2023Q1	dei	Entity Number Of Employees EntityNumberOfEmployees	23	number
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_zHHLuYG8izDj" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><span style="font-size: 10pt"><b><i><span id="xdx_861_zWuPFNDE2L2">Use of Estimates</span></i></b> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; impairment of finance receivables; allowance for credit losses; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.</span></p>
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11846000	usd
CY2023Q1	swkh	Disclosure Net Income Per Share Details Abstract DisclosureNetIncomePerShareDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureNetIncomePerShareDetailsAbstract_pn3n3_zh74jTbUpiV2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="padding-bottom: 1pt"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_491_20230101__20230331_zSZK88ESL3df" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_49C_20220101__20220331_zlbLwa4I3sc1" style="white-space: nowrap; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-size: 10pt"><b>March 31,</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Numerator:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40F_eus-gaap--ProfitLoss_zPlWqLZfzFCb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 74%; text-align: left; padding-left: 17.3pt">Net income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,635</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,478</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zrQOKj92DbTe" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,830</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_zvdrMEW1DqBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Effect of dilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z5VfwGyGxqkb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Weighted-average diluted shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,888</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_pid_z87PwByVBpkc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Basic net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pid_zImtkU8nnCQ8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Diluted net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	3478000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12833000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12830000	shares
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	42	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	58	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12875000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12888000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.36
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	119000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	300000	shares
CY2023Q1	swkh	Disclosure Finance Receivables Net Details Abstract DisclosureFinanceReceivablesNetDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureFinanceReceivablesNetDetailsAbstract_pn3n3_z48qmJesJjG6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230331_zOwFHEsyCRBj" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20221231_zMsayufQXALd" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zaaRFhXRWXki" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">202,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">188,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_z9osahnULEa9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,560</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">59,565</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maNRNzInv_zitZNtZ5Y73c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,401</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNRNzInv_zwmAzhBgdPX1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,786</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,846</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableNet_iTI_mtNRNzInv_zTzfksZSPYE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">236,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Notes Receivable Gross NotesReceivableGross	248824000	usd
CY2022Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	248401000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11786000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11846000	usd
CY2023Q1	us-gaap	Notes Receivable Net NotesReceivableNet	237038000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	236555000	usd
CY2023Q1	swkh	Disclosure Finance Receivables Net Details2 Abstract DisclosureFinanceReceivablesNetDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--DisclosureFinanceReceivablesNetDetails2Abstract_pn3n3_zS2c3135a6u4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20230101__20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zqXRn0DH9e34" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20230101__20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zzCgOo5a4yvc" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49E_20230101__20230331_zkuhMYNc2wAh" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49C_20220101__20220331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_z3TOP8rel5o2" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49C_20220101__20220331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zDjxVePxi01a" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20220101__20220331_z4Oy9YYMrWdc" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term<br/> Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term<br/> Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iS_zXa2MpCmbY17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 28%; text-align: left; text-indent: -8.65pt">Allowance at beginning of period, prior to adoption of ASU 2016-13</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">8,388</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">8,388</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinancingReceivableAllowanceForCreditLossesWriteOffs_iN_di_zkUn9Hq4dCn2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"><span style="font-size: 10pt">Write offs<sup id="xdx_F43_zTgJBxnbNYo9">(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0479">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,846</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,846</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0482">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0483">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0484">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLossesRecovery_z8oGc5Gcsqmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Recoveries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0486">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0489">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iS_zMBoStKUttHa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Effect of adoption of ASU 2016-13</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,886</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,786</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0497">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0498">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ProvisionForLoanLeaseAndOtherLosses_z00IgDvZvMZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Provision expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0500">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0502">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0505">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iE_zAcD779qwT72" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Allowance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,900</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,886</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 13pt; text-align: left"><span style="font-size: 10pt"><sup id="xdx_F0C_z8lSGG4KXou5">(1)</sup></span></td><td style="text-align: justify"><span id="xdx_F13_zD7QvQNns4Tl" style="font-size: 10pt">Reversal of finance receivable-specific ACL recognized in prior periods. No impact to consolidated statement of income for the three-months ended March 31, 2023. Please refer to Note 1 for further details.</span></td> </tr></table>
CY2021Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8388000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	11846000	usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Loss Excluding Accrued Interest FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest	11786000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11786000	usd
CY2022Q1	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8388000	usd
CY2023Q1	swkh	Disclosure Finance Receivables Net Details3 Abstract DisclosureFinanceReceivablesNetDetails3Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureFinanceReceivablesNetDetails3Abstract_pn3n3_zaEj5oIJS4Q3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 3)"> <tr style="vertical-align: bottom"> <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_497_20230331__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zkvM9Awlvqdd" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_497_20230331__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zcEgNmVkE3D1" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20230331_zBENphgbnO57" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20221231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_z1BZqbhHOijh" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_495_20221231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zx1T2UM2N7Ak" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_496_20221231_zEbSeIgY0bz9" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zJGoe4C56Z28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,844</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">181,520</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">193,364</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,304</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">177,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">188,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zhYlEhTFXFC5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,096</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">36,578</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">43,674</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,736</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,983</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,719</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesReceivableNet_iI_zo9y0UXUVAEa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,940</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">218,098</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,040</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">218,515</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">236,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Notes Receivable Net NotesReceivableNet	237038000	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	236555000	usd
CY2023Q1	swkh	Disclosure Finance Receivables Net Details4 Abstract DisclosureFinanceReceivablesNetDetails4Abstract	<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureFinanceReceivablesNetDetails4Abstract_pn3n3_zkSpxy7TCHX3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 4)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_48F_eus-gaap--FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear_iI_ztB8d3O29Bmk" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_481_eus-gaap--FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear_iI_z3LHqS6htnrl" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_482_eus-gaap--FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear_iI_z9yGx8jTU4gk" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear_iI_z86Em75pMqw2" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear_iI_zfURYJuA5dS5" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_487_eus-gaap--FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear_iI_zzlLqNZq18ff" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_484_eus-gaap--FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_iI_ziXf6bJauMNh" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="26" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: left; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prior</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Term Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_412_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zM9lDV3UXeMk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 30%; text-align: left; padding-left: 17.3pt">5</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0546">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">12,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">13,574</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">6,743</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">32,318</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_415_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zlUcZR0maavf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,955</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,853</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0556">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0558">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,558</td><td style="text-align: left"> </td></tr> <tr id="xdx_41E_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zUX2pquC2dR4" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,671</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0563">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,041</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,430</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,544</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--DoubtfulMember_zuEE0Vi1OURg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0571">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0572">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--UnlikelyToBeCollectedFinancingReceivableMember_z2JxQso8zSE7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">1</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0574">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,844</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0578">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0579">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,844</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_410_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zaccvQA2hgy7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Term Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,955</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,726</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,844</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,430</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202,264</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Royalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zI3r5d67v2h1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Green</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0588">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0590">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0592">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,902</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39,328</td><td style="text-align: left"> </td></tr> <tr id="xdx_414_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zBxMFLDG8iQ4" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Yellow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0595">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0596">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0597">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0598">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0599">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zwOA3H3iEr04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Red</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0602">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0603">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,239</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0605">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0606">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,856</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,095</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41A_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zLsmUYFpCVxk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Royalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0609">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0613">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,895</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_414_20230331_zfQTAxwAwcS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Total Finance Receivables</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">48,965</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">248,824</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year One Originated Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear	4955000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Two Originated Fiscal Year Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear	91756000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Three Originated Two Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear	48965000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Four Originated Three Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear	31039000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Year Five Originated Four Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear	37784000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Originated More Than Five Years Before Current Fiscal Year FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear	34325000	usd
CY2023Q1	us-gaap	Financing Receivable Excluding Accrued Interest Before Allowance For Credit Loss FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss	248824000	usd
CY2023Q1	swkh	Disclosure Intangible Assets Details Abstract DisclosureIntangibleAssetsDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_zTh8NjmoZQqd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_480_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_zB3RPu2xnhYc" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_48C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_zxfzFjgrmMtg" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_484_eus-gaap--IntangibleAssetsCurrent_iI_zFQGRfuyjPDj" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book<br/> Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book<br/> Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated<br/> Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_41C_20230331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zHN1fKLbsZag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 40%; text-indent: -8.65pt"><span style="font-size: 10pt">Licensing Agreement<sup id="xdx_F4F_zayBUjuhXcW2">(1)</sup></span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">21,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">7,476</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zRF0iIZqszN5" style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zsYvqBeizprg" style="width: 6%; text-align: right">21,509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsCurrent_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zYdNUoSuxmn" style="width: 6%; text-align: right">7,891</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_419_20230331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z9ne11CDyZp8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z7DcjXh1gpb2" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zuhTqRlIxQn2" style="text-align: right">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsCurrent_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zkSCa6zh4lF4" style="text-align: right">139</td><td style="text-align: left"> </td></tr> <tr id="xdx_412_20230331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzEKG9CiiYHj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">154</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zVi76lTorKOh" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoHaRNgJ5tu8" style="border-bottom: Black 1pt solid; text-align: right">80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zbuwS6bO151b" style="border-bottom: Black 1pt solid; text-align: right">160</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41E_20230331_zwQqht4Ktppd" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,086</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231_zNgTJ6Ol0Uol" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zLlTqc3WhuGj" style="border-bottom: Black 2.5pt double; text-align: right">21,660</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsCurrent_iI_c20221231_zcJDh0vbXp5f" style="border-bottom: Black 2.5pt double; text-align: right">8,190</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	29850000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	22086000	usd
CY2023Q1	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	7764000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	29850000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	21660000	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	8190000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2023Q1	swkh	Disclosure Intangible Assets Details2 Abstract DisclosureIntangibleAssetsDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zOvffFHvcVMd" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Fiscal Year</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230331_zUhc2UryQ6U7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzQY9_z9mhm14SZXKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 47%">Remainder of 2023</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_z3p2xRa0Epua" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,546</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zxyDnghn64vc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zm5XbDMCNt7e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zA4NLiJRFAWe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_z4TsRvsiLgwj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,713</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zWigsf0jYb1g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1277000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1546000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1076000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1076000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1076000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1713000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7764000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	10500000	usd
CY2022Q4	us-gaap	Line Of Credit Facility Fair Value Of Amount Outstanding LineOfCreditFacilityFairValueOfAmountOutstanding	2400000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	24500000	usd
CY2023Q1	swkh	Disclosure Commitments And Contingencies Details Abstract DisclosureCommitmentsAndContingenciesDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureCommitmentsAndContingenciesDetailsAbstract_pn3n3_zTXdH9Woy285" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"/><td/> <td style="text-align: left"/><td id="xdx_485_eus-gaap--CommitmentsAndContingencies_iI_pn3n6_zR2LdN4zQhj4" style="text-align: right"/><td style="text-align: left"/></tr> <tr id="xdx_418_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExeevoIncMember_zOMw9SbVC6E8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 47%; text-align: left">Exeevo, Inc.</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2.5</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41F_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DuoRoyaltyMember_zDtbz5LYtgSg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Duo Royalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.4</td><td style="text-align: left"> </td></tr> <tr id="xdx_410_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedMinderSystemsIncMember_zkoZ41NguP14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">MedMinder Systems, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SKNVMember_zpmPokUxWNSf" style="vertical-align: bottom; background-color: White"> <td>SKNV</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2.0</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41D_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember_zm1KM0UCntRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left">Total unfunded commitments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Disclosure Fair Value Measurements Details Abstract DisclosureFairValueMeasurementsDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_pn3n3_zCENKuLY0Mga" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zltVdIiNLNi9" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Total </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Carrying </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Value in </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Consolidated </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Balance </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Sheets</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zot2xaV6TyDi" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Quoted Prices </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>in Active </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Markets for </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Identical </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Assets </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>or Liabilities </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zej0ISmkzxld" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Significant </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Other </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Observable </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Inputs </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqzYb5BoJeJa" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Significant </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Unobservable </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Inputs </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_z5Pezat5AFh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zSLXh46GqnC9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 48%; text-align: left; text-indent: -8.65pt">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">683</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">683</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zC3eMu9xiKOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zZkcBfZSbfk5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ContingentConsiderationPayable_i01I_pn3n3_z8ny5lKb5sp7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DerivativeLiabilities_i01I_pn3n3_zVb04Azx8YSb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Derivative liability - foreign currency forward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0725">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0726">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Disclosure Fair Value Measurements Details2 Abstract DisclosureFairValueMeasurementsDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_pn3n3_zIUZHk4uz6Na" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20230101__20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z55JX02fmVea" style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td id="xdx_49F_20220101__20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3YaNoXCfVR3" style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2022</td></tr> <tr id="xdx_405_ecustom--WarrantAssets_iS_z9uP7h8m37g2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 35%; text-indent: -8.65pt">Fair value - December 31, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="padding-left: 8.65pt; width: 35%; text-indent: -8.65pt">Fair value - December 31, 2021</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarrantIssuances_z2KgoYTRYCW" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">445</td><td style="text-align: left"> </td><td> </td> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantsCanceled_za6rjzR8DR0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0769">—</span></td><td style="text-align: left"> </td><td> </td> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0770">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_zho0qaHTmhUk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(982</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(693</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--WarrantAssets_iE_znou7UsBTdw" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Fair value - March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">683</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Fair value - March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Disclosure Fair Value Measurements Details3 Abstract DisclosureFairValueMeasurementsDetails3Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureFairValueMeasurementsDetails3Abstract_zS9kdcKU2h6g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>March 31, 2023</b></span></td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: right"><span style="font-size: 10pt"><b>December 31, 2022</b></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; text-indent: -8.65pt">Dividend rate range</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="white-space: nowrap; width: 8%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zyzFZwm5AZfd">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="white-space: nowrap; width: 8%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zSjO43TQ8Y92">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Risk-free rate range</td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyez3DaHbOFa">3.6%</span> to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zK5XBePoR0B">4.1%</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zj6Ufg2lfwRk">4.0%</span> to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zyTsxATZQm4c">4.3%</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Expected life (years) range</td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zidX4axjLs83" title="::XDX::P2Y">2.0</span> to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2ocBZqvfCwh" title="::XDX::P6Y6M">6.5</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zG60995qJuf1" title="::XDX::P2Y">2.0</span> to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9SkWgugFYRa" title="::XDX::P6Y10M24D">6.9</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZqU6xi4LKu3">59.5%</span> to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zv28VbXtr7Oh">135.5%</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zuwtTdCi5N37">54.8%</span> to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zwdI3GspeiB6">139.4%</span></span></td><td style="text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Disclosure Fair Value Measurements Details4 Abstract DisclosureFairValueMeasurementsDetails4Abstract	<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureFairValueMeasurementsDetails4Abstract_pn3n3_zQ4GS7HndKS3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_zWB6nemHpaW6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Total </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Carrying </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Value in </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Consolidated </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Balance </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Sheets</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zHVXor1akAE4" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Quoted Prices </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>in Active </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Markets for </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Identical </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Assets </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>or Liabilities </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Level 1)</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zdlP6Zqh7DCa" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Significant </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Other </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Observable </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Inputs </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Level 2)</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zhWUE2inXJ7i" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Significant </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Unobservable </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Inputs </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>(Level 3)</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_430_c20230331_eus-gaap--InvestmentsFairValueDisclosure_iI_zqddB0ML6Pa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: bold; text-align: justify">March 31, 2023</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0801">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0802">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,994</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_433_c20221231_eus-gaap--InvestmentsFairValueDisclosure_iI_zN3d7jLJRKxi" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,545</td><td style="text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Disclosure Fair Value Measurements Details5 Abstract DisclosureFairValueMeasurementsDetails5Abstract	<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureFairValueMeasurementsDetails5Abstract_pn3n3_zg5AhaYXbUl9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--CarryingReportedAmountFairValueDisclosureMember_zp4QoMGxkpLl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying <br/> Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--EstimateOfFairValueFairValueDisclosureMember_zRw9oGDygUza" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zsd1nFUFHtbh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zAUnmk6PXuSj" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zpVah9aRMv17" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43F_c20230331_eus-gaap--FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_iB_zAUICH1noqgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20230331_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zyeLR2PzOF7c" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 35%; text-align: left; text-indent: -8.65pt">Finance receivables</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">237,038</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">237,038</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0823">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">237,038</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_43C_c20230331_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zErRQVEwxn2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0829">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20230331_ecustom--WarrantAssets_iI_zWhlF8UuxFob" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0834">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_432_c20230331_eus-gaap--FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_iB_zzuyBzDZVrDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_436_c20230331_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_z6vOWbEUjmel" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20230331_eus-gaap--DerivativeLiabilities_iI_zV6IXPGvhcb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Derivative liability - foreign currency forward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0852">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0853">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Disclosure Revenue Recognition Details Abstract DisclosureRevenueRecognitionDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureRevenueRecognitionDetailsAbstract_pn3n3_zUxt6qfGwf42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td id="xdx_491_20230101__20230331_zaOpkhIKLpvb" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td id="xdx_49D_20220101__20220331_zQX4GlWmtl41" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-size: 10pt"><b>Three Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><span style="font-size: 10pt"><b>March 31,</b></span></p></td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zVHkZL4B7bF4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; text-indent: -8.65pt">License Agreement</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">116</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpikvvF9COxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Pharmaceutical Development and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">118</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zDn951Tgifke" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">716</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Disclosure Revenue Recognition Details2 Abstract DisclosureRevenueRecognitionDetails2Abstract	<table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureRevenueRecognitionDetails2Abstract_pn3n3_zJfjn3gVJHTg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230331_zMYiP8oh1obe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<br/> 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_z00WoGOxZo72" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br/> 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zNbEi8uoyevd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; text-indent: -8.65pt">Deferred revenue</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">33</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">33</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_zrQ1hLC7bFw5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	33000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	33000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	33000	usd
CY2023Q1	swkh	Disclosure Segment Information Details Abstract DisclosureSegmentInformationDetailsAbstract	<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--DisclosureSegmentInformationDetailsAbstract_pn3n3_zFF7JsT5XCO1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49C_20230101__20230331__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zuF5qZq80x1j" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49E_20230101__20230331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zK29YrnfFit6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20230101__20230331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zTKX1RG0HY16" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20230101__20230331_zWJyyHuo5Ddl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance<br/> Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical <br/> Development and<br/> Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company<br/> and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_ecustom--RevenuesExcludingOtherRevenue_z4jK5rN1rvz6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,260</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,378</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueNotFromContractWithCustomerOther_zqVquz5Y3ikl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_zQ6uUmHVnVq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0941">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0942">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_znQD1LKH8e37" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0945">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">719</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0947">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">719</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_zmLfPnqb3qU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0950">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">648</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zxUyGlfl10Hj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,540</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherOperatingIncomeExpenseNet_zMSXCAswhWz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(796</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(796</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_zkUJuNxR6nbc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0965">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0966">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109</td><td style="text-align: left">) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109</td><td style="text-align: left">) </td></tr> <tr id="xdx_404_eus-gaap--ProfitLoss_zkn15FhV1vIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,676</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,635</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220331__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zulqn5dJBu0i" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20220101__20220331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zXYiKWE8uIRf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_492_20220101__20220331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_z9i06zanwzc3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_495_20220101__20220331_z6NsHfCdMdFh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance<br/> Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical <br/> Development and<br/> Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company <br/> and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_ecustom--RevenuesExcludingOtherRevenue_zeswajr3fyf5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,415</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">236</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,651</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueNotFromContractWithCustomerOther_zPYwCEoJgkk5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InterestExpense_zeXIJAPwLtij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0986">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_zcXocfnxmaq2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,901</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DepreciationAndAmortization_zY1yTmEqCdMb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">704</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0997">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">704</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_zOIcG3JFw7Kf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,160</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherOperatingIncomeExpenseNet_zoPrAtNmb3J6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(721</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(721</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_zmXrHLem0Yvj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1010">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,087</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ProfitLoss_znyfaaxD0jV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,924</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,110</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,478</td><td style="text-align: left"> </td></tr> </table>
CY2023Q1	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	9378000	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	33000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	182000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	719000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	648000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2540000	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-796000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-109000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	4635000	usd
CY2022Q1	swkh	Revenues Excluding Other Revenue RevenuesExcludingOtherRevenue	10651000	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer Other RevenueNotFromContractWithCustomerOther	480000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	80000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1901000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	704000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3160000	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-721000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1087000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	3478000	usd

CY2023Q1

dei

Entity Central Index Key

EntityCentralIndexKey

0001089907

CY2023Q1

dei

Amendment Flag

AmendmentFlag

false

CY2023Q1

dei

Current Fiscal Year End Date

CurrentFiscalYearEndDate

--12-31

CY2023Q1

dei

Document Fiscal Year Focus

DocumentFiscalYearFocus

2023

CY2023Q1

dei

Document Fiscal Period Focus

DocumentFiscalPeriodFocus

Q1

CY2023Q1

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

usd

CY2022Q1

us-gaap

Foreign Currency Transaction Gain Before Tax

ForeignCurrencyTransactionGainBeforeTax

usd

CY2023Q1

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

usd

CY2022Q1

us-gaap

Stock Issued During Period Value New Issues

StockIssuedDuringPeriodValueNewIssues

usd

CY2022Q1

us-gaap

Stock Issued During Period Value Restricted Stock Award Forfeitures

StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures

usd

CY2023Q1

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

usd

CY2022Q1

us-gaap

Foreign Currency Transaction Gain Before Tax

ForeignCurrencyTransactionGainBeforeTax

usd

CY2022Q1

swkh

Derivative Instrument Receivable

DerivativeInstrumentReceivable

usd

CY2022Q1

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

usd

CY2022Q1

us-gaap

Financing Receivable Allowance For Credit Losses Write Offs

FinancingReceivableAllowanceForCreditLossesWriteOffs

usd

CY2023Q1

us-gaap

Financing Receivable Allowance For Credit Losses Recovery

FinancingReceivableAllowanceForCreditLossesRecovery

usd

CY2022Q1

us-gaap

Financing Receivable Allowance For Credit Losses Recovery

FinancingReceivableAllowanceForCreditLossesRecovery

usd

CY2021Q4

us-gaap

Financing Receivable Allowance For Credit Loss Excluding Accrued Interest

FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest

usd

CY2023Q1

us-gaap

Provision For Loan Lease And Other Losses

ProvisionForLoanLeaseAndOtherLosses

usd

CY2023Q1

dei

Document Type

DocumentType

10-Q

CY2023Q1

dei

Document Quarterly Report

DocumentQuarterlyReport

true

CY2023Q1

dei

Document Period End Date

DocumentPeriodEndDate

2023-03-31

CY2023Q1

dei

Document Transition Report

DocumentTransitionReport

false

CY2023Q1

dei

Entity File Number

EntityFileNumber

001-39184

CY2023Q1

dei

Entity Registrant Name

EntityRegistrantName

SWK Holdings Corporation

CY2023Q1

dei

Entity Incorporation State Country Code

EntityIncorporationStateCountryCode

DE

CY2023Q1

dei

Entity Tax Identification Number

EntityTaxIdentificationNumber

77-0435679

CY2023Q1

dei

Entity Address Address Line1

EntityAddressAddressLine1

14755 Preston Road

CY2023Q1

dei

Entity Address Address Line2

EntityAddressAddressLine2

Suite 105

CY2023Q1

dei

Entity Address City Or Town

EntityAddressCityOrTown

Dallas

CY2023Q1

dei

Entity Address State Or Province

EntityAddressStateOrProvince

TX

CY2023Q1

dei

Entity Address Postal Zip Code

EntityAddressPostalZipCode

75254

CY2023Q1

dei

City Area Code

CityAreaCode

(972)

CY2023Q1

dei

Local Phone Number

LocalPhoneNumber

687-7250

CY2023Q1

dei

Security12b Title

Security12bTitle

Common Stock, par value $0.001 per share

CY2023Q1

dei

Trading Symbol

TradingSymbol

SWKH

CY2023Q1

dei

Security Exchange Name

SecurityExchangeName

NASDAQ

CY2023Q1

dei

Entity Current Reporting Status

EntityCurrentReportingStatus

Yes

CY2023Q1

dei

Entity Interactive Data Current

EntityInteractiveDataCurrent

Yes

CY2023Q1

dei

Entity Filer Category

EntityFilerCategory

Non-accelerated Filer

CY2023Q1

dei

Entity Small Business

EntitySmallBusiness

true

CY2023Q1

dei

Entity Emerging Growth Company

EntityEmergingGrowthCompany

false

CY2023Q1

dei

Entity Shell Company

EntityShellCompany

false

CY2023Q2

dei

Entity Common Stock Shares Outstanding

EntityCommonStockSharesOutstanding

12815167

shares

CY2023Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3244000

usd

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6156000

usd

CY2023Q1

us-gaap

Accounts Receivable Net

AccountsReceivableNet

4345000

usd

CY2022Q4

us-gaap

Accounts Receivable Net

AccountsReceivableNet

3094000

usd

CY2023Q1

us-gaap

Other Assets Current

OtherAssetsCurrent

1287000

usd

CY2022Q4

us-gaap

Other Assets Current

OtherAssetsCurrent

1114000

usd

CY2023Q1

us-gaap

Assets Current

AssetsCurrent

8876000

usd

CY2022Q4

us-gaap

Assets Current

AssetsCurrent

10364000

usd

CY2023Q1

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

11786000

usd

CY2022Q4

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

11846000

usd

CY2023Q1

us-gaap

Notes And Loans Receivable Net Current

NotesAndLoansReceivableNetCurrent

237038000

usd

CY2022Q4

us-gaap

Notes And Loans Receivable Net Current

NotesAndLoansReceivableNetCurrent

236555000

usd

CY2023Q1

us-gaap

Derivative Instruments And Hedges

DerivativeInstrumentsAndHedges

2750000

usd

CY2022Q4

us-gaap

Derivative Instruments And Hedges

DerivativeInstrumentsAndHedges

2750000

usd

CY2023Q1

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

66000

usd

CY2022Q4

us-gaap

Available For Sale Securities Debt Securities

AvailableForSaleSecuritiesDebtSecurities

76000

usd

CY2023Q1

us-gaap

Deferred Income Tax Assets Net

DeferredIncomeTaxAssetsNet

27128000

usd

CY2022Q4

us-gaap

Deferred Income Tax Assets Net

DeferredIncomeTaxAssetsNet

24480000

usd

CY2023Q1

swkh

Warrant Assets

WarrantAssets

683000

usd

CY2022Q4

swkh

Warrant Assets

WarrantAssets

1220000

usd

CY2023Q1

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

7764000

usd

CY2022Q4

us-gaap

Intangible Assets Net Excluding Goodwill

IntangibleAssetsNetExcludingGoodwill

8190000

usd

CY2023Q1

us-gaap

Goodwill

8404000

usd

CY2022Q4

us-gaap

Goodwill

8404000

usd

CY2023Q1

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

5627000

usd

CY2022Q4

us-gaap

Property Plant And Equipment Net

PropertyPlantAndEquipmentNet

5840000

usd

CY2023Q1

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

2401000

usd

CY2022Q4

us-gaap

Other Assets Noncurrent

OtherAssetsNoncurrent

1742000

usd

CY2023Q1

us-gaap

Assets

300737000

usd

CY2022Q4

us-gaap

Assets

299621000

usd

CY2023Q1

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

1833000

usd

CY2022Q4

us-gaap

Accounts Payable And Accrued Liabilities Current

AccountsPayableAndAccruedLiabilitiesCurrent

3902000

usd

CY2023Q1

us-gaap

Lines Of Credit Current

LinesOfCreditCurrent

10482000

usd

CY2022Q4

us-gaap

Lines Of Credit Current

LinesOfCreditCurrent

2445000

usd

CY2023Q1

us-gaap

Liabilities Current

LiabilitiesCurrent

12315000

usd

CY2022Q4

us-gaap

Liabilities Current

LiabilitiesCurrent

6347000

usd

CY2023Q1

us-gaap

Business Combination Contingent Consideration Liability

BusinessCombinationContingentConsiderationLiability

11200000

usd

CY2022Q4

us-gaap

Business Combination Contingent Consideration Liability

BusinessCombinationContingentConsiderationLiability

11200000

usd

CY2023Q1

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

2837000

usd

CY2022Q4

us-gaap

Other Liabilities Noncurrent

OtherLiabilitiesNoncurrent

2145000

usd

CY2023Q1

us-gaap

Liabilities

26352000

usd

CY2022Q4

us-gaap

Liabilities

19692000

usd

CY2023Q1

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2022Q4

us-gaap

Preferred Stock Par Or Stated Value Per Share

PreferredStockParOrStatedValuePerShare

0.001

CY2023Q1

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

shares

CY2022Q4

us-gaap

Preferred Stock Shares Authorized

PreferredStockSharesAuthorized

5000000

shares

CY2023Q1

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2023Q1

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2022Q4

us-gaap

Preferred Stock Shares Issued

PreferredStockSharesIssued

0

shares

CY2022Q4

us-gaap

Preferred Stock Shares Outstanding

PreferredStockSharesOutstanding

0

shares

CY2023Q1

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2022Q4

us-gaap

Common Stock Par Or Stated Value Per Share

CommonStockParOrStatedValuePerShare

0.001

CY2023Q1

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

250000000

shares

CY2022Q4

us-gaap

Common Stock Shares Authorized

CommonStockSharesAuthorized

250000000

shares

CY2023Q1

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

12830399

shares

CY2023Q1

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

12830399

shares

CY2022Q4

us-gaap

Common Stock Shares Issued

CommonStockSharesIssued

12843157

shares

CY2022Q4

us-gaap

Common Stock Shares Outstanding

CommonStockSharesOutstanding

12843157

shares

CY2023Q1

us-gaap

Common Stock Value

CommonStockValue

12000

usd

CY2022Q4

us-gaap

Common Stock Value

CommonStockValue

12000

usd

CY2023Q1

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

4430426000

usd

CY2022Q4

us-gaap

Additional Paid In Capital

AdditionalPaidInCapital

4430922000

usd

CY2023Q1

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-4156053000

usd

CY2022Q4

us-gaap

Retained Earnings Accumulated Deficit

RetainedEarningsAccumulatedDeficit

-4151005000

usd

CY2023Q1

us-gaap

Stockholders Equity

StockholdersEquity

274385000

usd

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

279929000

usd

CY2023Q1

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

300737000

usd

CY2022Q4

us-gaap

Liabilities And Stockholders Equity

LiabilitiesAndStockholdersEquity

299621000

usd

CY2023Q1

us-gaap

Interest And Fee Income Loans And Leases

InterestAndFeeIncomeLoansAndLeases

9260000

usd

CY2022Q1

us-gaap

Interest And Fee Income Loans And Leases

InterestAndFeeIncomeLoansAndLeases

10415000

usd

CY2023Q1

swkh

Pharmaceutical Development Revenue

PharmaceuticalDevelopmentRevenue

118000

usd

CY2022Q1

swkh

Pharmaceutical Development Revenue

PharmaceuticalDevelopmentRevenue

236000

usd

CY2023Q1

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

33000

usd

CY2022Q1

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

480000

usd

CY2023Q1

us-gaap

Revenues

9411000

usd

CY2022Q1

us-gaap

Revenues

11131000

usd

CY2023Q1

us-gaap

Interest Expense

InterestExpense

182000

usd

CY2022Q1

us-gaap

Interest Expense

InterestExpense

80000

usd

CY2023Q1

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

719000

usd

CY2022Q1

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1901000

usd

CY2023Q1

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

648000

usd

CY2022Q1

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

704000

usd

CY2023Q1

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

2540000

usd

CY2022Q1

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

3160000

usd

CY2023Q1

us-gaap

Costs And Expenses

CostsAndExpenses

-5322000

usd

CY2022Q1

us-gaap

Costs And Expenses

CostsAndExpenses

-5286000

usd

CY2023Q1

us-gaap

Unrealized Gain Loss On Derivatives

UnrealizedGainLossOnDerivatives

-982000

usd

CY2022Q1

us-gaap

Unrealized Gain Loss On Derivatives

UnrealizedGainLossOnDerivatives

-693000

usd

CY2022Q1

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

-28000

usd

CY2023Q1

us-gaap

Foreign Currency Transaction Gain Before Tax

ForeignCurrencyTransactionGainBeforeTax

186000

usd

CY2023Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

4526000

usd

CY2022Q1

us-gaap

Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments

IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

4565000

usd

CY2023Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-109000

usd

CY2022Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1087000

usd

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

4635000

usd

CY2022Q1

us-gaap

Profit Loss

ProfitLoss

3478000

usd

CY2023Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.36

CY2022Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.27

CY2023Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.36

CY2022Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.27

CY2023Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12833000

shares

CY2022Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12830000

shares

CY2023Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12875000

shares

CY2022Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12888000

shares

CY2022Q4

us-gaap

Stockholders Equity

StockholdersEquity

279929000

usd

CY2023Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

35000

usd

CY2023Q1

swkh

Effect Of Adoption Of Accounting Standard

EffectOfAdoptionOfAccountingStandard

-9683000

usd

CY2023Q1

us-gaap

Stock Repurchased During Period Value

StockRepurchasedDuringPeriodValue

531000

usd

CY2023Q1

us-gaap

Net Income Loss

NetIncomeLoss

4635000

usd

CY2023Q1

us-gaap

Stockholders Equity

StockholdersEquity

274385000

usd

CY2021Q4

us-gaap

Stockholders Equity

StockholdersEquity

267236000

usd

CY2022Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

85000

usd

CY2022Q1

us-gaap

Net Income Loss

NetIncomeLoss

3478000

usd

CY2022Q1

us-gaap

Stockholders Equity

StockholdersEquity

270799000

usd

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

4635000

usd

CY2022Q1

us-gaap

Profit Loss

ProfitLoss

3478000

usd

CY2023Q1

us-gaap

Finance Lease Right Of Use Asset Amortization

FinanceLeaseRightOfUseAssetAmortization

68000

usd

CY2022Q1

us-gaap

Finance Lease Right Of Use Asset Amortization

FinanceLeaseRightOfUseAssetAmortization

56000

usd

CY2023Q1

us-gaap

Amortization Of Financing Costs

AmortizationOfFinancingCosts

15000

usd

CY2022Q1

us-gaap

Amortization Of Financing Costs

AmortizationOfFinancingCosts

14000

usd

CY2023Q1

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

-122000

usd

CY2022Q1

us-gaap

Deferred Income Taxes And Tax Credits

DeferredIncomeTaxesAndTaxCredits

1079000

usd

CY2023Q1

us-gaap

Fair Value Adjustment Of Warrants

FairValueAdjustmentOfWarrants

982000

usd

CY2022Q1

us-gaap

Fair Value Adjustment Of Warrants

FairValueAdjustmentOfWarrants

693000

usd

CY2022Q1

us-gaap

Marketable Securities Unrealized Gain Loss

MarketableSecuritiesUnrealizedGainLoss

-28000

usd

CY2023Q1

us-gaap

Foreign Currency Transaction Gain Before Tax

ForeignCurrencyTransactionGainBeforeTax

186000

usd

CY2023Q1

us-gaap

Amortization Of Deferred Loan Origination Fees Net

AmortizationOfDeferredLoanOriginationFeesNet

1466000

usd

CY2022Q1

us-gaap

Amortization Of Deferred Loan Origination Fees Net

AmortizationOfDeferredLoanOriginationFeesNet

421000

usd

CY2023Q1

us-gaap

Paid In Kind Interest

PaidInKindInterest

351000

usd

CY2022Q1

us-gaap

Paid In Kind Interest

PaidInKindInterest

734000

usd

CY2023Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

35000

usd

CY2022Q1

us-gaap

Share Based Compensation

ShareBasedCompensation

85000

usd

CY2023Q1

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

648000

usd

CY2022Q1

us-gaap

Depreciation Depletion And Amortization

DepreciationDepletionAndAmortization

704000

usd

CY2023Q1

us-gaap

Increase Decrease In Interest And Dividends Receivable

IncreaseDecreaseInInterestAndDividendsReceivable

1251000

usd

CY2022Q1

us-gaap

Increase Decrease In Interest And Dividends Receivable

IncreaseDecreaseInInterestAndDividendsReceivable

176000

usd

CY2023Q1

swkh

Derivative Instrument Receivable

DerivativeInstrumentReceivable

-388000

usd

CY2023Q1

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

915000

usd

CY2022Q1

us-gaap

Increase Decrease In Other Operating Assets

IncreaseDecreaseInOtherOperatingAssets

225000

usd

CY2023Q1

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-1412000

usd

CY2022Q1

us-gaap

Increase Decrease In Accounts Payable And Accrued Liabilities

IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

-270000

usd

CY2023Q1

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

664000

usd

CY2022Q1

us-gaap

Net Cash Provided By Used In Operating Activities

NetCashProvidedByUsedInOperatingActivities

4311000

usd

CY2023Q1

us-gaap

Payments To Acquire Finance Receivables

PaymentsToAcquireFinanceReceivables

12990000

usd

CY2022Q1

us-gaap

Payments To Acquire Finance Receivables

PaymentsToAcquireFinanceReceivables

22700000

usd

CY2023Q1

swkh

Proceeds Repayment Of Finance Receivables

ProceedsRepaymentOfFinanceReceivables

1906000

usd

CY2022Q1

swkh

Proceeds Repayment Of Finance Receivables

ProceedsRepaymentOfFinanceReceivables

16978000

usd

CY2023Q1

swkh

Marketable Investment Principal Payment

MarketableInvestmentPrincipalPayment

10000

usd

CY2022Q1

swkh

Marketable Investment Principal Payment

MarketableInvestmentPrincipalPayment

13000

usd

CY2023Q1

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

8000

usd

CY2022Q1

us-gaap

Payments To Acquire Property Plant And Equipment

PaymentsToAcquirePropertyPlantAndEquipment

58000

usd

CY2023Q1

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-11082000

usd

CY2022Q1

us-gaap

Net Cash Provided By Used In Investing Activities

NetCashProvidedByUsedInInvestingActivities

-5767000

usd

CY2023Q1

us-gaap

Proceeds From Repayments Of Lines Of Credit

ProceedsFromRepaymentsOfLinesOfCredit

8037000

usd

CY2022Q1

us-gaap

Proceeds From Repayments Of Lines Of Credit

ProceedsFromRepaymentsOfLinesOfCredit

-8000

usd

CY2023Q1

us-gaap

Payments For Repurchase Of Common Stock

PaymentsForRepurchaseOfCommonStock

531000

usd

CY2023Q1

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

7506000

usd

CY2022Q1

us-gaap

Net Cash Provided By Used In Financing Activities

NetCashProvidedByUsedInFinancingActivities

-8000

usd

CY2023Q1

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-2912000

usd

CY2022Q1

us-gaap

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect

CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

-1464000

usd

CY2022Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

6156000

usd

CY2021Q4

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

42863000

usd

CY2023Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

3244000

usd

CY2022Q1

us-gaap

Cash And Cash Equivalents At Carrying Value

CashAndCashEquivalentsAtCarryingValue

41399000

usd

CY2023Q1

dei

Entity Number Of Employees

EntityNumberOfEmployees

23

number

CY2023Q1

us-gaap

Use Of Estimates

UseOfEstimates

Use of Estimates The preparation of the Company’s consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition; stock-based compensation; valuation of interest and accounts receivable; impairment of finance receivables; allowance for credit losses; long-lived assets; property and equipment; intangible assets; goodwill; valuation of warrants and other investments; contingent consideration; income taxes; and contingencies and litigation, among others. Some of these judgments can be subjective and complex, and consequently, actual results may differ from these estimates. The Company’s estimates often are based on complex judgments, probabilities and assumptions that it believes to be reasonable but that are inherently uncertain and unpredictable. For any given individual estimate or assumption made by the Company, there may also be other estimates or assumptions that are reasonable. The Company regularly evaluates its estimates and assumptions using historical experience and other factors, including the economic environment. As future events and their effects cannot be determined with precision, the Company’s estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause changes to those estimates and assumptions. Market conditions, such as illiquid credit markets, health crises such as the COVID-19 global pandemic, volatile equity markets, and economic downturns, can increase the uncertainty already inherent in the Company’s estimates and assumptions. The Company adjusts its estimates and assumptions when facts and circumstances indicate the need for change. Those changes generally will be reflected in our consolidated financial statements on a prospective basis unless they are required to be treated retrospectively under the relevant accounting standard. It is possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts.

CY2022Q4

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

11846000

usd

CY2023Q1

swkh

Disclosure Net Income Per Share Details Abstract

DisclosureNetIncomePerShareDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--DisclosureNetIncomePerShareDetailsAbstract_pn3n3_zh74jTbUpiV2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Income per Share (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="padding-bottom: 1pt"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_491_20230101__20230331_zSZK88ESL3df" style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td style="white-space: nowrap; text-align: center"/> <td id="xdx_49C_20220101__20220331_zlbLwa4I3sc1" style="white-space: nowrap; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Three Months Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Numerator:</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr id="xdx_40F_eus-gaap--ProfitLoss_zPlWqLZfzFCb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 74%; text-align: left; padding-left: 17.3pt">Net income</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">4,635</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,478</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zrQOKj92DbTe" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,833</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,830</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_pid_zvdrMEW1DqBg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Effect of dilutive securities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">58</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z5VfwGyGxqkb" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Weighted-average diluted shares</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,875</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">12,888</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EarningsPerShareBasic_pid_z87PwByVBpkc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Basic net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EarningsPerShareDiluted_pid_zImtkU8nnCQ8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Diluted net income per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.27</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

4635000

usd

CY2022Q1

us-gaap

Profit Loss

ProfitLoss

3478000

usd

CY2023Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12833000

shares

CY2022Q1

us-gaap

Weighted Average Number Of Shares Outstanding Basic

WeightedAverageNumberOfSharesOutstandingBasic

12830000

shares

CY2023Q1

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

42

shares

CY2022Q1

us-gaap

Weighted Average Number Diluted Shares Outstanding Adjustment

WeightedAverageNumberDilutedSharesOutstandingAdjustment

58

shares

CY2023Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12875000

shares

CY2022Q1

us-gaap

Weighted Average Number Of Diluted Shares Outstanding

WeightedAverageNumberOfDilutedSharesOutstanding

12888000

shares

CY2023Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.36

CY2022Q1

us-gaap

Earnings Per Share Basic

EarningsPerShareBasic

0.27

CY2023Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.36

CY2022Q1

us-gaap

Earnings Per Share Diluted

EarningsPerShareDiluted

0.27

CY2023Q1

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

119000

shares

CY2022Q1

us-gaap

Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

300000

shares

CY2023Q1

swkh

Disclosure Finance Receivables Net Details Abstract

DisclosureFinanceReceivablesNetDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureFinanceReceivablesNetDetailsAbstract_pn3n3_z48qmJesJjG6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20230331_zOwFHEsyCRBj" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20221231_zMsayufQXALd" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zaaRFhXRWXki" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">202,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">188,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--NotesReceivableGross_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_z9osahnULEa9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,560</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">59,565</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableGross_iI_maNRNzInv_zitZNtZ5Y73c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 17.3pt">Total before allowance for credit losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,824</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">248,401</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iNI_di_msNRNzInv_zwmAzhBgdPX1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Allowance for credit losses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,786</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,846</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--NotesReceivableNet_iTI_mtNRNzInv_zTzfksZSPYE2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">236,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

us-gaap

Notes Receivable Gross

NotesReceivableGross

248824000

usd

CY2022Q4

us-gaap

Notes Receivable Gross

NotesReceivableGross

248401000

usd

CY2023Q1

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

11786000

usd

CY2022Q4

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

11846000

usd

CY2023Q1

us-gaap

Notes Receivable Net

NotesReceivableNet

237038000

usd

CY2022Q4

us-gaap

Notes Receivable Net

NotesReceivableNet

236555000

usd

CY2023Q1

swkh

Disclosure Finance Receivables Net Details2 Abstract

DisclosureFinanceReceivablesNetDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--DisclosureFinanceReceivablesNetDetails2Abstract_pn3n3_zS2c3135a6u4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20230101__20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zqXRn0DH9e34" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20230101__20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zzCgOo5a4yvc" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49E_20230101__20230331_zkuhMYNc2wAh" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49C_20220101__20220331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_z3TOP8rel5o2" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49C_20220101__20220331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zDjxVePxi01a" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20220101__20220331_z4Oy9YYMrWdc" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Term Loans</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Royalties</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iS_zXa2MpCmbY17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 28%; text-align: left; text-indent: -8.65pt">Allowance at beginning of period, prior to adoption of ASU 2016-13</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,846</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">8,388</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">8,388</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinancingReceivableAllowanceForCreditLossesWriteOffs_iN_di_zkUn9Hq4dCn2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Write offs(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,846</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(11,846</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FinancingReceivableAllowanceForCreditLossesRecovery_z8oGc5Gcsqmb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Recoveries</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest_iS_zMBoStKUttHa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Effect of adoption of ASU 2016-13</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,900</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,886</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,786</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ProvisionForLoanLeaseAndOtherLosses_z00IgDvZvMZ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Provision expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinancingReceivableAllowanceForCreditLosses_iE_zAcD779qwT72" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; padding-left: 17.3pt">Allowance at end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,900</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,886</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,786</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,388</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 13pt; text-align: left">(1)</td><td style="text-align: justify">Reversal of finance receivable-specific ACL recognized in prior periods. No impact to consolidated statement of income for the three-months ended March 31, 2023. Please refer to Note 1 for further details.</td> </tr></table>

CY2021Q4

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

8388000

usd

CY2023Q1

us-gaap

Financing Receivable Allowance For Credit Losses Write Offs

FinancingReceivableAllowanceForCreditLossesWriteOffs

11846000

usd

CY2022Q4

us-gaap

Financing Receivable Allowance For Credit Loss Excluding Accrued Interest

FinancingReceivableAllowanceForCreditLossExcludingAccruedInterest

11786000

usd

CY2023Q1

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

11786000

usd

CY2022Q1

us-gaap

Financing Receivable Allowance For Credit Losses

FinancingReceivableAllowanceForCreditLosses

8388000

usd

CY2023Q1

swkh

Disclosure Finance Receivables Net Details3 Abstract

DisclosureFinanceReceivablesNetDetails3Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--DisclosureFinanceReceivablesNetDetails3Abstract_pn3n3_zaEj5oIJS4Q3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 3)"> <tr style="vertical-align: bottom"> <td style="text-align: center"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_497_20230331__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_zkvM9Awlvqdd" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_497_20230331__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zcEgNmVkE3D1" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20230331_zBENphgbnO57" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49A_20221231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--NonperformingFinancingReceivableMember_z1BZqbhHOijh" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_495_20221231__us-gaap--FinancialInstrumentPerformanceStatusAxis__us-gaap--PerformingFinancingReceivableMember_zx1T2UM2N7Ak" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_496_20221231_zEbSeIgY0bz9" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Nonaccrual</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Performing</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zJGoe4C56Z28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left">Term loans</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,844</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">181,520</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">193,364</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">11,304</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">177,532</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">188,836</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--NotesReceivableNet_iI_hus-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zhYlEhTFXFC5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Royalty purchases</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,096</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">36,578</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">43,674</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,736</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">40,983</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">47,719</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesReceivableNet_iI_zo9y0UXUVAEa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt">Total carrying value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,940</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">218,098</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">237,038</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">18,040</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">218,515</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">236,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

us-gaap

Notes Receivable Net

NotesReceivableNet

237038000

usd

CY2022Q4

us-gaap

Notes Receivable Net

NotesReceivableNet

236555000

usd

CY2023Q1

swkh

Disclosure Finance Receivables Net Details4 Abstract

DisclosureFinanceReceivablesNetDetails4Abstract

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureFinanceReceivablesNetDetails4Abstract_pn3n3_zkSpxy7TCHX3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Finance Receivables, Net (Details 4)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_48F_eus-gaap--FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear_iI_ztB8d3O29Bmk" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_481_eus-gaap--FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear_iI_z3LHqS6htnrl" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_482_eus-gaap--FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear_iI_z9yGx8jTU4gk" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear_iI_z86Em75pMqw2" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_485_eus-gaap--FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear_iI_zfURYJuA5dS5" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_487_eus-gaap--FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear_iI_zzlLqNZq18ff" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_484_eus-gaap--FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss_iI_ziXf6bJauMNh" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="26" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: left; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2021</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2020</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2019</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Prior</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Term Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_412_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zM9lDV3UXeMk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; width: 30%; text-align: left; padding-left: 17.3pt">5</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">12,001</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">13,574</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">6,743</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">32,318</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_415_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zlUcZR0maavf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">4</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,955</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">49,853</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63,558</td><td style="text-align: left"> </td></tr> <tr id="xdx_41E_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zUX2pquC2dR4" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">3</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,671</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,402</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,041</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,430</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,544</td><td style="text-align: left"> </td></tr> <tr id="xdx_415_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--DoubtfulMember_zuEE0Vi1OURg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">2</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--UnlikelyToBeCollectedFinancingReceivableMember_z2JxQso8zSE7" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">1</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,844</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,844</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_410_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceTermLoansMember_zaccvQA2hgy7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Term Loans</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,955</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76,525</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,726</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,844</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">37,784</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,430</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202,264</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Royalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_41B_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--PassMember_zI3r5d67v2h1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Green</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">15,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">19,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4,902</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39,328</td><td style="text-align: left"> </td></tr> <tr id="xdx_414_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SpecialMentionMember_zBxMFLDG8iQ4" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Yellow</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137</td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember__us-gaap--InternalCreditAssessmentAxis__us-gaap--SubstandardMember_zwOA3H3iEr04" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Red</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,239</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,856</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">7,095</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41A_20230331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LifeScienceRoyaltyPurchasesMember_zLsmUYFpCVxk" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 25.95pt">Subtotal - Royalties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,231</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,239</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,195</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,895</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,560</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_414_20230331_zfQTAxwAwcS9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Total Finance Receivables</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,955</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">91,756</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">48,965</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">31,039</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,784</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,325</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">248,824</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

us-gaap

Financing Receivable Excluding Accrued Interest Year One Originated Current Fiscal Year

FinancingReceivableExcludingAccruedInterestYearOneOriginatedCurrentFiscalYear

4955000

usd

CY2023Q1

us-gaap

Financing Receivable Excluding Accrued Interest Year Two Originated Fiscal Year Before Current Fiscal Year

FinancingReceivableExcludingAccruedInterestYearTwoOriginatedFiscalYearBeforeCurrentFiscalYear

91756000

usd

CY2023Q1

us-gaap

Financing Receivable Excluding Accrued Interest Year Three Originated Two Years Before Current Fiscal Year

FinancingReceivableExcludingAccruedInterestYearThreeOriginatedTwoYearsBeforeCurrentFiscalYear

48965000

usd

CY2023Q1

us-gaap

Financing Receivable Excluding Accrued Interest Year Four Originated Three Years Before Current Fiscal Year

FinancingReceivableExcludingAccruedInterestYearFourOriginatedThreeYearsBeforeCurrentFiscalYear

31039000

usd

CY2023Q1

us-gaap

Financing Receivable Excluding Accrued Interest Year Five Originated Four Years Before Current Fiscal Year

FinancingReceivableExcludingAccruedInterestYearFiveOriginatedFourYearsBeforeCurrentFiscalYear

37784000

usd

CY2023Q1

us-gaap

Financing Receivable Excluding Accrued Interest Originated More Than Five Years Before Current Fiscal Year

FinancingReceivableExcludingAccruedInterestOriginatedMoreThanFiveYearsBeforeCurrentFiscalYear

34325000

usd

CY2023Q1

us-gaap

Financing Receivable Excluding Accrued Interest Before Allowance For Credit Loss

FinancingReceivableExcludingAccruedInterestBeforeAllowanceForCreditLoss

248824000

usd

CY2023Q1

swkh

Disclosure Intangible Assets Details Abstract

DisclosureIntangibleAssetsDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureIntangibleAssetsDetailsAbstract_pn3n3_zTh8NjmoZQqd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_480_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_zB3RPu2xnhYc" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_48C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_zxfzFjgrmMtg" style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_484_eus-gaap--IntangibleAssetsCurrent_iI_zFQGRfuyjPDj" style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/> <td style="white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Gross Book Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Accumulated Amortization</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Net Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_41C_20230331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zHN1fKLbsZag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 40%; text-indent: -8.65pt">Licensing Agreement(1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">21,924</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">7,476</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zRF0iIZqszN5" style="width: 6%; text-align: right">29,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zsYvqBeizprg" style="width: 6%; text-align: right">21,509</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsCurrent_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_fKDEp_zYdNUoSuxmn" style="width: 6%; text-align: right">7,891</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_419_20230331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z9ne11CDyZp8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Trade names and trademarks</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">76</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z7DcjXh1gpb2" style="text-align: right">210</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zuhTqRlIxQn2" style="text-align: right">71</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--IntangibleAssetsCurrent_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zkSCa6zh4lF4" style="text-align: right">139</td><td style="text-align: left"> </td></tr> <tr id="xdx_412_20230331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzEKG9CiiYHj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Customer relationships</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">154</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zVi76lTorKOh" style="border-bottom: Black 1pt solid; text-align: right">240</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoHaRNgJ5tu8" style="border-bottom: Black 1pt solid; text-align: right">80</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--IntangibleAssetsCurrent_iI_c20221231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zbuwS6bO151b" style="border-bottom: Black 1pt solid; text-align: right">160</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41E_20230331_zwQqht4Ktppd" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,086</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_iI_c20221231_zNgTJ6Ol0Uol" style="border-bottom: Black 2.5pt double; text-align: right">29,850</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20221231_zLlTqc3WhuGj" style="border-bottom: Black 2.5pt double; text-align: right">21,660</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsCurrent_iI_c20221231_zcJDh0vbXp5f" style="border-bottom: Black 2.5pt double; text-align: right">8,190</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

29850000

usd

CY2023Q1

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

22086000

usd

CY2023Q1

us-gaap

Intangible Assets Current

IntangibleAssetsCurrent

7764000

usd

CY2022Q4

us-gaap

Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill

BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

29850000

usd

CY2022Q4

us-gaap

Finite Lived Intangible Assets Accumulated Amortization

FiniteLivedIntangibleAssetsAccumulatedAmortization

21660000

usd

CY2022Q4

us-gaap

Intangible Assets Current

IntangibleAssetsCurrent

8190000

usd

CY2023Q1

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

400000

usd

CY2022Q1

us-gaap

Amortization Of Intangible Assets

AmortizationOfIntangibleAssets

500000

usd

CY2023Q1

swkh

Disclosure Intangible Assets Details2 Abstract

DisclosureIntangibleAssetsDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--DisclosureIntangibleAssetsDetails2Abstract_pn3n3_zOvffFHvcVMd" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto" summary="xdx: Disclosure - Intangible Assets (Details 2)"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left">Fiscal Year</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20230331_zUhc2UryQ6U7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzQY9_z9mhm14SZXKa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 47%">Remainder of 2023</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,277</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzQY9_z3p2xRa0Epua" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,546</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzQY9_zxyDnghn64vc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_maFLIANzQY9_zm5XbDMCNt7e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_maFLIANzQY9_zA4NLiJRFAWe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,076</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_maFLIANzQY9_z4TsRvsiLgwj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,713</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzQY9_zWigsf0jYb1g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,764</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Next Twelve Months

FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths

1277000

usd

CY2023Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Two

FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

1546000

usd

CY2023Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Three

FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

1076000

usd

CY2023Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Four

FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

1076000

usd

CY2023Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

1076000

usd

CY2023Q1

us-gaap

Finite Lived Intangible Assets Amortization Expense After Year Five

FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive

1713000

usd

CY2023Q1

us-gaap

Finite Lived Intangible Assets Net

FiniteLivedIntangibleAssetsNet

7764000

usd

CY2023Q1

us-gaap

Line Of Credit Facility Fair Value Of Amount Outstanding

LineOfCreditFacilityFairValueOfAmountOutstanding

10500000

usd

CY2022Q4

us-gaap

Line Of Credit Facility Fair Value Of Amount Outstanding

LineOfCreditFacilityFairValueOfAmountOutstanding

2400000

usd

CY2023Q1

us-gaap

Line Of Credit Facility Remaining Borrowing Capacity

LineOfCreditFacilityRemainingBorrowingCapacity

24500000

usd

CY2023Q1

swkh

Disclosure Commitments And Contingencies Details Abstract

DisclosureCommitmentsAndContingenciesDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureCommitmentsAndContingenciesDetailsAbstract_pn3n3_zTXdH9Woy285" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%" summary="xdx: Disclosure - Commitments and Contingencies (Details)"> <tr style="vertical-align: bottom"> <td style="text-align: left"/><td/> <td style="text-align: left"/><td id="xdx_485_eus-gaap--CommitmentsAndContingencies_iI_pn3n6_zR2LdN4zQhj4" style="text-align: right"/><td style="text-align: left"/></tr> <tr id="xdx_418_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ExeevoIncMember_zOMw9SbVC6E8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 47%; text-align: left">Exeevo, Inc.</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2.5</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_41F_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DuoRoyaltyMember_zDtbz5LYtgSg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Duo Royalty</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.4</td><td style="text-align: left"> </td></tr> <tr id="xdx_410_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MedMinderSystemsIncMember_zkoZ41NguP14" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">MedMinder Systems, Inc.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td></tr> <tr id="xdx_411_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SKNVMember_zpmPokUxWNSf" style="vertical-align: bottom; background-color: White"> <td>SKNV</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2.0</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_41D_20230331__us-gaap--FinancingReceivableRecordedInvestmentByClassOfFinancingReceivableAxis__us-gaap--UnfundedLoanCommitmentMember_zm1KM0UCntRi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left">Total unfunded commitments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11.9</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Disclosure Fair Value Measurements Details Abstract

DisclosureFairValueMeasurementsDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureFairValueMeasurementsDetailsAbstract_pn3n3_zCENKuLY0Mga" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zltVdIiNLNi9" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Total Carrying Value in Consolidated Balance Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zot2xaV6TyDi" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zej0ISmkzxld" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Significant Other Observable Inputs (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zqzYb5BoJeJa" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_40F_ecustom--FinancialAssetsAbstract_iB_z5Pezat5AFh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--WarrantAssets_i01I_pn3n3_zSLXh46GqnC9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 48%; text-align: left; text-indent: -8.65pt">Warrant assets</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">683</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">683</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--InvestmentsFairValueDisclosure_i01I_pn3n3_zC3eMu9xiKOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--FinancialLiabilitiesAbstract_iB_zZkcBfZSbfk5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--ContingentConsiderationPayable_i01I_pn3n3_z8ny5lKb5sp7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DerivativeLiabilities_i01I_pn3n3_zVb04Azx8YSb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Derivative liability - foreign currency forward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Disclosure Fair Value Measurements Details2 Abstract

DisclosureFairValueMeasurementsDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88D_ecustom--DisclosureFairValueMeasurementsDetails2Abstract_pn3n3_zIUZHk4uz6Na" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td id="xdx_496_20230101__20230331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z55JX02fmVea" style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td id="xdx_49F_20220101__20220331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3YaNoXCfVR3" style="white-space: nowrap; font-weight: bold; text-align: center"> </td> <td style="white-space: nowrap; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2022</td></tr> <tr id="xdx_405_ecustom--WarrantAssets_iS_z9uP7h8m37g2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 35%; text-indent: -8.65pt">Fair value - December 31, 2022</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">1,220</td><td style="width: 1%; text-align: left"> </td><td style="width: 4%"> </td> <td style="padding-left: 8.65pt; width: 35%; text-indent: -8.65pt">Fair value - December 31, 2021</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">3,419</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--WarrantIssuances_z2KgoYTRYCW" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">445</td><td style="text-align: left"> </td><td> </td> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarrantsCanceled_za6rjzR8DR0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Canceled</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--FairValueOptionChangesInFairValueGainLoss1_zho0qaHTmhUk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(982</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Change in fair value</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(693</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_ecustom--WarrantAssets_iE_znou7UsBTdw" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Fair value - March 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">683</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-left: 8.65pt; text-indent: -8.65pt">Fair value - March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,878</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Disclosure Fair Value Measurements Details3 Abstract

DisclosureFairValueMeasurementsDetails3Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureFairValueMeasurementsDetails3Abstract_zS9kdcKU2h6g" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 3)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: right">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold; text-align: left"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: right">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; text-indent: -8.65pt">Dividend rate range</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="white-space: nowrap; width: 8%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zyzFZwm5AZfd">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="white-space: nowrap; width: 8%; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp0_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember_zSjO43TQ8Y92">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Risk-free rate range</td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zyez3DaHbOFa">3.6% to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zK5XBePoR0B">4.1%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zj6Ufg2lfwRk">4.0% to <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zyTsxATZQm4c">4.3%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Expected life (years) range</td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zidX4axjLs83" title="::XDX::P2Y">2.0 to <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z2ocBZqvfCwh" title="::XDX::P6Y6M">6.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zG60995qJuf1" title="::XDX::P2Y">2.0 to <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtxH_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_z9SkWgugFYRa" title="::XDX::P6Y10M24D">6.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Expected volatility range</td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zZqU6xi4LKu3">59.5% to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20230101__20230331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zv28VbXtr7Oh">135.5%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="white-space: nowrap; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zuwtTdCi5N37">54.8% to <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_c20220101__20220331__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zwdI3GspeiB6">139.4%</td><td style="text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Disclosure Fair Value Measurements Details4 Abstract

DisclosureFairValueMeasurementsDetails4Abstract

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureFairValueMeasurementsDetails4Abstract_pn3n3_zQ4GS7HndKS3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 4)"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_zWB6nemHpaW6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Total Carrying Value in Consolidated Balance Sheets</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zHVXor1akAE4" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4B7_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zdlP6Zqh7DCa" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Significant Other Observable Inputs (Level 2)</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td><td style="white-space: nowrap; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByMeasurementFrequencyAxis_us-gaap--FairValueMeasurementsNonrecurringMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zhWUE2inXJ7i" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_430_c20230331_eus-gaap--InvestmentsFairValueDisclosure_iI_zqddB0ML6Pa5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: bold; text-align: justify">March 31, 2023</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,994</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">2,994</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_433_c20221231_eus-gaap--InvestmentsFairValueDisclosure_iI_zN3d7jLJRKxi" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">December 31, 2022</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,545</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3,545</td><td style="text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Disclosure Fair Value Measurements Details5 Abstract

DisclosureFairValueMeasurementsDetails5Abstract

<table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureFairValueMeasurementsDetails5Abstract_pn3n3_zg5AhaYXbUl9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 5)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BD_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--CarryingReportedAmountFairValueDisclosureMember_zp4QoMGxkpLl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Carrying Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BB_us-gaap--FairValueByMeasurementBasisAxis_us-gaap--EstimateOfFairValueFairValueDisclosureMember_zRw9oGDygUza" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Fair Value</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BF_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel1Member_zsd1nFUFHtbh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BC_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel2Member_zAUnmk6PXuSj" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_4BE_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zpVah9aRMv17" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_43F_c20230331_eus-gaap--FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_iB_zAUICH1noqgd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20230331_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_zyeLR2PzOF7c" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 35%; text-align: left; text-indent: -8.65pt">Finance receivables</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">237,038</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">237,038</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">237,038</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_43C_c20230331_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_zErRQVEwxn2f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Marketable investments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66</td><td style="text-align: left"> </td></tr> <tr id="xdx_430_c20230331_ecustom--WarrantAssets_iI_zWhlF8UuxFob" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Warrant assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">683</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-indent: -8.65pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_432_c20230331_eus-gaap--FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_iB_zzuyBzDZVrDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Financial Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_436_c20230331_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_z6vOWbEUjmel" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Contingent consideration payable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">11,200</td><td style="text-align: left"> </td></tr> <tr id="xdx_435_c20230331_eus-gaap--DerivativeLiabilities_iI_zV6IXPGvhcb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Derivative liability - foreign currency forward</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">367</td><td style="text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Disclosure Revenue Recognition Details Abstract

DisclosureRevenueRecognitionDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_889_ecustom--DisclosureRevenueRecognitionDetailsAbstract_pn3n3_zUxt6qfGwf42" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td id="xdx_491_20230101__20230331_zaOpkhIKLpvb" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/> <td id="xdx_49D_20220101__20220331_zQX4GlWmtl41" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Three Months Ended March 31,</td><td style="white-space: nowrap; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zVHkZL4B7bF4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; text-indent: -8.65pt">License Agreement</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">116</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zpikvvF9COxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Pharmaceutical Development and other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">118</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">600</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_hus-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zDn951Tgifke" style="vertical-align: bottom; background-color: White"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total contract revenue</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">118</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">716</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Disclosure Revenue Recognition Details2 Abstract

DisclosureRevenueRecognitionDetails2Abstract

<table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureRevenueRecognitionDetails2Abstract_pn3n3_zJfjn3gVJHTg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Recognition (Details 2)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20230331_zMYiP8oh1obe" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20221231_z00WoGOxZo72" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; font-weight: bold; text-align: left; text-indent: -8.65pt">Pharmaceutical Development Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredRevenue_iI_zNbEi8uoyevd" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; width: 74%; text-align: left; text-indent: -8.65pt">Deferred revenue</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">33</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 8%; text-align: right">33</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ContractWithCustomerLiability_iI_zrQ1hLC7bFw5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -8.65pt; text-align: left; padding-left: 17.3pt">Total contract liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

CY2023Q1

us-gaap

Deferred Revenue

DeferredRevenue

33000

usd

CY2022Q4

us-gaap

Deferred Revenue

DeferredRevenue

33000

usd

CY2023Q1

us-gaap

Contract With Customer Liability

ContractWithCustomerLiability

33000

usd

CY2022Q4

us-gaap

Contract With Customer Liability

ContractWithCustomerLiability

33000

usd

CY2023Q1

swkh

Disclosure Segment Information Details Abstract

DisclosureSegmentInformationDetailsAbstract

<table cellpadding="0" cellspacing="0" id="xdx_898_ecustom--DisclosureSegmentInformationDetailsAbstract_pn3n3_zFF7JsT5XCO1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Segment Information (Details)"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49C_20230101__20230331__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zuF5qZq80x1j" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_49E_20230101__20230331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zK29YrnfFit6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20230101__20230331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_zTKX1RG0HY16" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_493_20230101__20230331_zWJyyHuo5Ddl" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2023</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_404_ecustom--RevenuesExcludingOtherRevenue_z4jK5rN1rvz6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,260</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">118</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">9,378</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--RevenueNotFromContractWithCustomerOther_zqVquz5Y3ikl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">33</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestExpense_zQ6uUmHVnVq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">182</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--ResearchAndDevelopmentExpense_znQD1LKH8e37" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">719</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">719</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DepreciationAndAmortization_zmLfPnqb3qU5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">648</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_zxUyGlfl10Hj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">727</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,540</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherOperatingIncomeExpenseNet_zMSXCAswhWz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(796</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(796</td><td style="text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_zkUJuNxR6nbc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109</td><td style="text-align: left">) </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(109</td><td style="text-align: left">) </td></tr> <tr id="xdx_404_eus-gaap--ProfitLoss_zkn15FhV1vIb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,283</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,676</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,635</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"/><td style="font-weight: bold; padding-bottom: 1pt"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_498_20220101__20220331__us-gaap--FinancingReceivablePortfolioSegmentAxis__us-gaap--FinanceReceivablesMember_zulqn5dJBu0i" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_490_20220101__20220331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--PharmaceuticalDevelopmentServicesMember_zXYiKWE8uIRf" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_492_20220101__20220331__us-gaap--FinancingReceivablePortfolioSegmentAxis__custom--HoldingCompanyAndOtherMember_z9i06zanwzc3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/> <td id="xdx_495_20220101__20220331_z6NsHfCdMdFh" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"/><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"/></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Three Months Ended March 31, 2022</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 8.65pt; white-space: nowrap; text-align: center; text-indent: -8.65pt"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Finance Receivables</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Pharmaceutical Development and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Holding Company and Other</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Consolidated</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_ecustom--RevenuesExcludingOtherRevenue_zeswajr3fyf5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; width: 48%; text-indent: -8.65pt">Revenue</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,415</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">236</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">—</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">10,651</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RevenueNotFromContractWithCustomerOther_zPYwCEoJgkk5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other revenue</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">480</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InterestExpense_zeXIJAPwLtij" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--ResearchAndDevelopmentExpense_zcXocfnxmaq2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Manufacturing, research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,901</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DepreciationAndAmortization_zY1yTmEqCdMb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">704</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">704</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--GeneralAndAdministrativeExpense_zOIcG3JFw7Kf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,035</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,023</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,160</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherOperatingIncomeExpenseNet_zoPrAtNmb3J6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Other expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(721</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(721</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_zmXrHLem0Yvj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Income tax expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,087</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ProfitLoss_znyfaaxD0jV6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 8.65pt; text-align: left; text-indent: -8.65pt">Net income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,512</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,924</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,110</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,478</td><td style="text-align: left"> </td></tr> </table>

CY2023Q1

swkh

Revenues Excluding Other Revenue

RevenuesExcludingOtherRevenue

9378000

usd

CY2023Q1

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

33000

usd

CY2023Q1

us-gaap

Interest Expense

InterestExpense

182000

usd

CY2023Q1

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

719000

usd

CY2023Q1

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

648000

usd

CY2023Q1

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

2540000

usd

CY2023Q1

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-796000

usd

CY2023Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

-109000

usd

CY2023Q1

us-gaap

Profit Loss

ProfitLoss

4635000

usd

CY2022Q1

swkh

Revenues Excluding Other Revenue

RevenuesExcludingOtherRevenue

10651000

usd

CY2022Q1

us-gaap

Revenue Not From Contract With Customer Other

RevenueNotFromContractWithCustomerOther

480000

usd

CY2022Q1

us-gaap

Interest Expense

InterestExpense

80000

usd

CY2022Q1

us-gaap

Research And Development Expense

ResearchAndDevelopmentExpense

1901000

usd

CY2022Q1

us-gaap

Depreciation And Amortization

DepreciationAndAmortization

704000

usd

CY2022Q1

us-gaap

General And Administrative Expense

GeneralAndAdministrativeExpense

3160000

usd

CY2022Q1

us-gaap

Other Operating Income Expense Net

OtherOperatingIncomeExpenseNet

-721000

usd

CY2022Q1

us-gaap

Income Tax Expense Benefit

IncomeTaxExpenseBenefit

1087000

usd

CY2022Q1

us-gaap

Profit Loss

ProfitLoss

3478000

usd

Name	View Source	Status
0001552781-23-000266-index-headers.html	Edgar Link	pending
0001552781-23-000266-index.html	Edgar Link	pending
0001552781-23-000266.txt	Edgar Link	pending
0001552781-23-000266-xbrl.zip	Edgar Link	pending
e23255001.jpg	Edgar Link	pending
e23255_ex31-1.htm	Edgar Link	pending
e23255_ex31-2.htm	Edgar Link	pending
e23255_ex32-1.htm	Edgar Link	pending
e23255_ex32-2.htm	Edgar Link	pending
e23255_swkh-10q.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
e23255_swkh-10q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
swkh-20230331.xsd	Edgar Link	pending
swkh-20230331_def.xml	Edgar Link	unprocessable
swkh-20230331_cal.xml	Edgar Link	unprocessable
swkh-20230331_lab.xml	Edgar Link	unprocessable
swkh-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SWKH
SWK Holdings Corp Stock $swkh

2023 Q2 Form 10-Q Financial Statement

#000155278123000266 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWKH SWK Holdings Corp Stock $swkh

2023 Q2 Form 10-Q Financial Statement

#000155278123000266 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SWKH
SWK Holdings Corp Stock $swkh